Smith & Nephew plc (NYSE:SNN) – Investment analysts at Northcoast Research boosted their Q2 2019 earnings estimates for Smith & Nephew in a research note issued on Monday, May 13th. Northcoast Research analyst D. Keiser now anticipates that the medical equipment provider will post earnings per share of $0.92 for the quarter, up from their prior estimate of $0.91.
A number of other research analysts have also weighed in on the company. Zacks Investment Research raised Smith & Nephew from a “hold” rating to a “buy” rating and set a $47.00 price target on the stock in a research note on Wednesday. Canaccord Genuity reissued a “buy” rating and set a $6.00 price target on shares of Smith & Nephew in a research note on Friday, May 3rd. Finally, BNP Paribas lowered Smith & Nephew from an “outperform” rating to a “neutral” rating in a research note on Friday, February 8th. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $26.50.
Several institutional investors and hedge funds have recently modified their holdings of SNN. Bank of New York Mellon Corp raised its position in shares of Smith & Nephew by 18.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 76,184 shares of the medical equipment provider’s stock worth $2,827,000 after buying an additional 11,873 shares during the period. Marshall Wace LLP purchased a new position in shares of Smith & Nephew in the 3rd quarter worth $708,000. Quadrant Capital Group LLC raised its position in shares of Smith & Nephew by 180.5% in the 4th quarter. Quadrant Capital Group LLC now owns 3,136 shares of the medical equipment provider’s stock worth $111,000 after buying an additional 2,018 shares during the period. FNY Investment Advisers LLC purchased a new position in shares of Smith & Nephew in the 4th quarter worth $616,000. Finally, Lenox Wealth Management Inc. purchased a new position in shares of Smith & Nephew in the 4th quarter worth $590,000. 8.95% of the stock is currently owned by institutional investors and hedge funds.
About Smith & Nephew
Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.